PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2026Frontiers in Medicine0 citationsOpen Access

Protocol: Comparative efficacy of 2 mL vs. 5 mL 0.375% ropivacaine in subparaneural upper trunk brachial plexus block for postoperative analgesia after arthroscopic shoulder surgery—a randomized noninferiority trial

JLJie LouYZYu ZhangJCJ K Chen

Key Points

  • This research aims to compare the efficacy of 2 mL versus 5 mL of 0.375% ropivacaine for postoperative pain relief while minimizing diaphragm complications.
  • Prospective, single-center, randomized, non-inferiority trial
  • 100 patients undergoing elective arthroscopic shoulder surgery randomized 1:1 to receive 2 mL or 5 mL of ropivacaine
  • Endpoints include NRS pain score and incidence of hemidiaphragmatic paresis.
  • The pre-rescue NRS pain score will be measured immediately after consciousness in the PACU, with a non-inferiority margin of 1 point.
  • Incidence of ipsilateral hemidiaphragmatic paresis will be assessed before PACU discharge.
  • Secondary outcomes include diaphragmatic function and other recovery indicators.

Abstract

Introduction Interscalene brachial plexus block (ISB) is the first-line analgesic technique for arthroscopic shoulder surgery, but it is associated with a 90% incidence of ipsilateral hemidiaphragmatic paresis (HDP), which severely limits its application in patients with preexisting pulmonary dysfunction. All currently available modified nerve block techniques have failed to achieve a 0% incidence of HDP while maintaining satisfactory analgesic efficacy. Our preliminary study demonstrated that subparaneural injection of 2 mL 0.375% ropivacaine at the bifurcation of the brachial plexus upper trunk provided excellent postoperative analgesia with no observed cases of HDP. Methods and analysis This is a prospective, single-center, randomized, non-inferiority trial conducted at Ningbo No.6 Hospital, China. A total of 100 patients undergoing elective arthroscopic shoulder surgery will be randomized in a 1:1 ratio to receive either 2 mL or 5 mL of 0.375% ropivacaine via ultrasound-guided subparaneural injection at the upper trunk bifurcation. The dual co-primary endpoints are the pre-rescue Numerical Rating Scale (NRS) pain score immediately after full consciousness in the post-anesthesia care unit (PACU) (non-inferiority margin = 1 point) and the incidence of ipsilateral HDP assessed before PACU discharge. Secondary outcomes include diaphragmatic function parameters, pulmonary function, perioperative analgesic consumption, recovery indicators, and adverse events. All statistical analyses will be performed according to the pre-specified statistical analysis plan, with the intention-to-treat population as the primary analysis set. Clinical trial registration http://www.chictr.org.cn , ChiCTR2500114139.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lou et al. (2026) studied this question.

synapsesocial.com/papers/6a1d20f302fbce9130637303https://doi.org/10.3389/fmed.2026.1865264
Ask AI
Helpful
Bookmark
Share
View Full Paper